IL17A and systemic lupus erythematosus: Unlike many approved biologic targets in SLE treatment, which belong to upstream components of the cellular cascade (e.g., pDCs and B cells), both IL-17 and IL-36 can act locally and synergistically or complementarily to promote inflammation and fibrosis.